Publications by authors named "Nitin Rai"

6 Publications

  • Page 1 of 1

Outcomes of Trauma Victims with Cardiac Arrest Who Survived to Intensive Care Unit Admission in a Level 1 Apex Indian Trauma Centre: A Retrospective Cohort Study.

Indian J Crit Care Med 2021 Dec;25(12):1408-1412

Department of Anaesthesiology, All India Institute of Medical Sciences, New Delhi, India.

Background And Aims: The prognosis of patients with cardiac arrest following trauma is poor. Our objectives were: (1) to determine outcomes of patients following in-hospital cardiac arrest posttrauma and admitted to the intensive care unit (ICU) and (2) to identify characteristics associated with in-hospital mortality.

Materials And Methods: This was a single-center retrospective analysis of patients admitted to ICU after resuscitation following in-hospital cardiac arrest between January 2017 and July 2018. Patients with isolated head injuries and multiple cardiac arrests were excluded. Bivariate analysis was done to determine a significant association between baseline characteristics and in-hospital mortality.

Results: A total of 37 patients were included. About 35.1% of trauma subjects survived hospital discharge. Bivariate analysis showed positive association between admission Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores with in-hospital mortality. Other characteristics, such as age, duration of cardiopulmonary resuscitation (CPR), and serum lactate levels on admission, were not associated with in-hospital mortality.

Conclusion: Despite being at lower survival following a cardiac arrest after trauma, approximately one-third of the patients survived hospital discharge. This implies that aggressive support of this population is not necessarily futile. Optimization of postresuscitation physiological factors and their impacts on outcomes for these patients need further studies.

How To Cite This Article: Soni KD, Rai N, Aggarwal R, Trikha A. Outcomes of Trauma Victims with Cardiac Arrest Who Survived to Intensive Care Unit Admission in a Level 1 Apex Indian Trauma Centre: A Retrospective Cohort Study. Indian J Crit Care Med 2021;25(12):1408-1412.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5005/jp-journals-10071-24057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693116PMC
December 2021

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: Is Sequela the Bigger Threat?

Indian J Crit Care Med 2021 Feb;25(2):245-246

All India Institute of Medical Sciences, New Delhi, India.

Rai N, Baidya DK. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: Is Sequela the Bigger Threat? Indian J Crit Care Med 2021;25(2):245-246.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5005/jp-journals-10071-23734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922440PMC
February 2021

Regulatory Requirements for Quality Control of Unani Medicines.

J AOAC Int 2020 Jun;103(3):634-648

Pharmacopoeia Commission for Indian Medicine and Homoeopathy, PLIM Campus, Ghaziabad 201002, India.

Compliance with pharmacopeial standards is mandatory to ensure the quality, safety, and efficacy of medicines. In India, allopathy, Ayurveda, Siddha, Unani, and homeopathy are the recognized systems of medicine and come under the provisions of different regulations. Promulgation of the "Drugs and Cosmetics Act, 1940" and the rules thereunder provide a regulatory framework for medicines of all of these systems and also prescribe "Pharmacopoeia and Formularies" for regulatory quality standards. Unlike in many other countries, the Act prescribes independent pharmacopeias for each system of medicine. The Unani Pharmacopoeia of India (UPI) and the National Formulary of Unani Medicine are the regulatory compendia for quality standards and manufacturing of Unani medicines, respectively. The Pharmacopoeia consists of Part I (single drugs) and Part II (formulations). Unani medicines are presented as classical or patent and proprietary formulations prepared using single ingredients or multiple ingredients of plant, animal, mineral, and/or metal origin. UPI Part I is published in six volumes comprising 298 monographs on Unani drugs derived from plants (single drugs). Part II is published in three volumes encompassing formulations, standard operating procedures, and quality standards for 150 classical formulations of Unani medicines, which are chosen from the National Formularies of Unani Medicine. The National Formulary of Unani Medicine is published in six parts comprising 1229 formulations of Unani medicines. Each monograph of the Pharmacopoeia provides specific analytical parameters and limits (standards) to ensure the quality of drugs or medicines. This communication reviews the UPI, the National Formulary of Unani Medicine, regulatory quality standards (parameters), and analytical techniques adopted for pharmacopeial standards of Unani drugs and medicines.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5740/jaoacint.19-0285DOI Listing
June 2020

Inserting politics and history in conservation.

Conserv Biol 2013 Apr;27(2):425-8

Ashoka Trust for Research in Ecology and the Environment, Bangalore, India.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/cobi.12026DOI Listing
April 2013

Rights, governance, and conservation of biological diversity.

Conserv Biol 2011 Jun 10;25(3):639-41. Epub 2011 Feb 10.

Sustainability Science Program, Harvard University, Cambridge, MA 02138, USA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1523-1739.2010.01640.xDOI Listing
June 2011

Exploration of rate-limiting conformational state for 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl][1,1'-biphenyl]-2-ols and N(omega)-oxides (tebuquine analogues) for antimalarial activity using molecular shape analysis and molecular field analysis studies.

J Chem Inf Model 2007 May-Jun;47(3):1087-96. Epub 2007 Apr 11.

Structural Biology and Bioinformatics Division, Indian Institute of Chemical Biology (CSIR), Kolkata 700032, India.

Tebuquine is a 4-aminoquinoline that shows significantly more potency as an antimalarial than amodiaquine and chloroquine both in vitro and in vivo. To explore the conformation in the rate-limiting step and to elucidate pharmacophoric properties of tebuquine-related analogues, molecular shape analysis (MSA) along with molecular field analysis (MFA) methods were applied on a series of 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl][1,1'-biphenyl]-2-ol analogues and their Nomega-oxides possessing antimalarial activity. The study was performed using 45 compounds in which 37 molecules were taken as a training set for the derivation of the 3D quantitative structure-activity relationship models and eight molecules were kept as a test set to evaluate the predictive ability of the derived models. Both methods were analyzed in terms of their predictive abilities and produced comparable results with good conventional and cross-validated r2 values (0.908 and 0.886, respectively, for the MFA model and 0.846 and 0.812, respectively, for the MSA model). In external data set prediction, the MSA model scored much better than MFA. Steric, electrostatic, and hydrogen-bond donor/acceptor fields of molecules were found to be relevant descriptors for structure-activity relationships. The inclusion of polar solvent-accessible charged surface area and spatial descriptors in the MSA model generation resulted in a model with significant predictive ability for the test set molecules. This indicates the importance of the orientation of conformationally favored molecules inside the receptor site and solvation of the charged surfaces of the molecule by a polar solvent for the activity of the molecule. The results provided the appropriate tools for predicting the affinity of related compounds using a ligand-based approach, and for guiding the design and synthesis of novel and more potent antimalarial agents.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1021/ci600570rDOI Listing
September 2007
-->